Table 4.

Summary of immune-mediated adverse events (AEs) for which immune-modulating medication was used*

Event, n (%)	Nivolumab (n=18)		Nivolumab plus ipilimumab (n=21)		Nivolumab plus ipilimumab plus cobimetinib (n=30)
	Any grade	Grade 3/4	Any grade	Grade 3/4	Any grade	Grade 3/4
Rash	0	0	2 (10)	0	5 (17)	0
Diarrhea	1 (6)	0	4 (19)	1 (5)	1 (3)	0
Maculopapular rash	2 (11)	1 (6)	0	0	3 (10)	1 (3)
AST increased	0	0	2 (10)	2 (10)	1 (3)	0
Colitis	1 (6)	1 (6)	1 (5)	1 (5)	0	0
ALT increased	0	0	1 (5)	1 (5)	1 (3)	0
Pneumonitis	0	0	0	0	2 (7)	0
Blood bilirubin increased	0	0	1 (5)	1 (5)	0	0
Hyperbilirubinemia	0	0	1 (5)	1 (5)	0	0
Autoimmune thyroiditis	0	0	1 (5)	1 (5)	0	0
Vesicular rash	0	0	0	0	1 (3)	1 (3)
Adrenal insufficiency	0	0	0	0	1 (3)	1 (3)
Hyperthyroidism	0	0	1 (5)	0	0	0

*Endocrine AEs (adrenal insufficiency, hypothyroidism/thyroiditis, hyperthyroidism, diabetes mellitus, and hypophysitis) were considered immune-mediated AEs regardless of immune-modulating medication use, as endocrine drug reactions are often managed without immune-modulating medication.

ALT, alanine aminotransferase; AST, aspartate aminotransferase.